ArticleArchives of pharmacal research2026
M2 microglial exosomal miR-1949 ameliorates sepsis-associated encephalopathy through DKK1/Wnt/β-catenin-mediated microglial repolarization.
Article in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated encephalopathy (SAE), the most common neurological complication of sepsis with high mortality, lacks effective treatments. Although microglia play a significant role in SAE pathogenesis, the mechanisms of M2 microglial exosomes (M2-EXOs) and their microRNAs (miRNAs) remain unclear. The present study demonstrated that both M2 microglial conditioned media (M2-CM) and M2-EXO promote the phenotypic transformation of M1 microglia toward the M2 phenotype. In M2-EXO, among the differentially expressed miRNAs, miR-1949 exhibited the most significant difference. The dual-luciferase assay showed that miR-1949 could bind to the 3'UTR of Dickkopf-related protein 1 (DKK1). Further experiments confirmed that M2-EXO-miR-1949 mimic mediated microglial phenotypic transformation by inhibiting DKK1 and activating the Wnt/β-catenin pathway. Notably, a single injection of M2-EXO (10 μg/mouse, i.c.v.) or M2-EXO-miR-1949 mimic (0.1 nmol/mouse, i.c.v.) significantly reduced the mouse sepsis score (MSS), decreased cortical neural cell damage in SAE mice induced by lipopolysaccharide (LPS), inhibiting abnormal microglial activation and alleviating neuroinflammation. Meanwhile, M2-EXO-miR-1949 mimic markedly inhibited DKK1 and activated the Wnt/β-catenin pathway in vivo. What's more, the effects of M2-EXO-miR-1949 mimic were reversed by the Wnt/β-catenin pathway inhibitor XAV939. In contrast, the effect of M2-EXO-miR-1949 inhibitor (0.1 nmol/mouse, i.c.v.) was opposite to that of M2-EXO-miR-1949 mimic. Furthermore, co-transfection of the M2-EXO-miR-1949 mimic and inhibitor mutually neutralized their opposing effects, resulting in no significant changes in the expression of inflammatory and pathway-related markers, thereby confirming the functional specificity of exosomal miR-1949. In summary, the present study indicates that M2-EXO, especially its contained miR-1949, ameliorates LPS-induced SAE in mice through inhibiting DKK1 to activate the Wnt/β-catenin pathway, thereby leading to microglial phenotypic transformation and neuroinflammation inhibition. This study reveals a novel mechanism by which M2-EXO and miRNA ameliorate SAE, providing a theoretical basis for further studies.
Indexed as
Identifiers
42313350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.